Literature DB >> 18707907

Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

Jin-Song Shen1, Xing-Li Meng, David F Moore, Jane M Quirk, James A Shayman, Raphael Schiffmann, Christine R Kaneski.   

Abstract

Fabry disease, an X-linked systemic vasculopathy, is caused by a deficiency of alpha-galactosidase A resulting in globotriaosylceramide (Gb(3)) storage in cells. The pathogenic role of Gb(3) in the disease is not known. Based on previous work, we tested the hypothesis that accumulation of Gb(3) in the vascular endothelium of Fabry disease is associated with increased production of reactive oxygen species (ROS) and increased expression of cell adhesion molecules. Gb(3)-loading resulted in increased intracellular ROS production in cultured vascular endothelial cells in a dose-dependent manner. Increased Gb(3) also induced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin. Reduction of endogenous Gb(3) by treatment of the cells with an inhibitor of glycosphingolipid synthase or alpha-galactosidase A led to decreased expression of adhesion molecules. Plasma from Fabry patients significantly increased ROS generation in endothelial cells when compared with plasma from non-Fabry controls. This effect was not influenced by reduction of intracellular Gb(3). This study provided direct evidence that excess intracellular Gb(3) induces oxidative stress and up-regulates the expression of cellular adhesion molecules in vascular endothelial cells. In addition, other factors in patient's plasma may also contribute to oxidative stress in Fabry vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707907      PMCID: PMC2593623          DOI: 10.1016/j.ymgme.2008.06.016

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

Review 1.  Role of oxidative modifications in atherosclerosis.

Authors:  Roland Stocker; John F Keaney
Journal:  Physiol Rev       Date:  2004-10       Impact factor: 37.312

2.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

3.  Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis.

Authors:  Daniel T Eitzman; Peter F Bodary; Yuechun Shen; Christian G Khairallah; Susan R Wild; Akira Abe; Jacqueline Shaffer-Hartman; James A Shayman
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

4.  Uptake and metabolism of a fluorescent sulfatide analogue in cultured skin fibroblasts.

Authors:  E Monti; A Preti; A Novati; M F Aleo; M L Clemente; S Marchesini
Journal:  Biochim Biophys Acta       Date:  1992-02-20

5.  Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study.

Authors:  David F Moore; Frank Ye; Marie-Luise Brennan; Surya Gupta; Bruce A Barshop; Robert D Steiner; William J Rhead; Roscoe O Brady; Stanley L Hazen; Raphael Schiffmann
Journal:  J Magn Reson Imaging       Date:  2004-10       Impact factor: 4.813

6.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.

Authors:  J F Leeuwenberg; E F Smeets; J J Neefjes; M A Shaffer; T Cinek; T M Jeunhomme; T J Ahern; W A Buurman
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

7.  Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives.

Authors:  M D Ullman; R H McCluer
Journal:  J Lipid Res       Date:  1977-05       Impact factor: 5.922

8.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Authors:  William R Wilcox; Maryam Banikazemi; Nathalie Guffon; Stephen Waldek; Philip Lee; Gabor E Linthorst; Robert J Desnick; Dominique P Germain
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

9.  CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.

Authors:  L Jardim; L Vedolin; I V D Schwartz; M G Burin; C Cecchin; L Kalakun; U Matte; F Aesse; C Pitta-Pinheiro; J Marconato; R Giugliani
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 10.  Adhesion molecules and atherosclerosis.

Authors:  Stefan Blankenberg; Sandrine Barbaux; Laurence Tiret
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

View more
  62 in total

Review 1.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

2.  Oxidative stress biomarkers in Fabry disease: is there a room for them?

Authors:  C Simoncini; S Torri; V Montano; L Chico; F Gruosso; A Tuttolomondo; A Pinto; I Simonetta; V Cianci; A Salviati; V Vicenzi; G Marchi; D Girelli; D Concolino; S Sestito; M Zedde; G Siciliano; Michelangelo Mancuso
Journal:  J Neurol       Date:  2020-07-27       Impact factor: 4.849

3.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Authors:  Janet Hsu; Daniel Serrano; Tridib Bhowmick; Kishan Kumar; Yang Shen; Yuan Chia Kuo; Carmen Garnacho; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

4.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Authors:  Justin J Kang; Nayiri M Kaissarian; Karl C Desch; Robert J Kelly; Liming Shu; Peter F Bodary; James A Shayman
Journal:  Kidney Int       Date:  2018-11-22       Impact factor: 10.612

5.  Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders.

Authors:  Xing-Li Meng; Jin-Song Shen; Shiho Kawagoe; Toya Ohashi; Roscoe O Brady; Yoshikatsu Eto
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

6.  Altered Met receptor phosphorylation and LRP1-mediated uptake in cells lacking carbohydrate-dependent lysosomal targeting.

Authors:  Megan Aarnio-Peterson; Peng Zhao; Seok-Ho Yu; Courtney Christian; Heather Flanagan-Steet; Lance Wells; Richard Steet
Journal:  J Biol Chem       Date:  2017-07-19       Impact factor: 5.157

Review 7.  Can we use statins to prevent stroke in Fabry disease?

Authors:  J M Politei
Journal:  J Inherit Metab Dis       Date:  2009-06-02       Impact factor: 4.982

8.  Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.

Authors:  Jason Papademetriou; Carmen Garnacho; Daniel Serrano; Tridib Bhowmick; Edward H Schuchman; Silvia Muro
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

Review 9.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.